Dr. Carmona is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Barnhart Cancer Center
769 Medical Center Ct
Chula Vista, CA 91911
Summary
- I am a board certified radiation oncologist. I completed my clinical training at the University of Pennsylvania and have experience in a variety of radiotherapy technologies, including intensity modulated proton therapy (IMPT), MRI-guided radiation therapy (MRgRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic radiosurgery (SRS), stereotactic ablative radiotherapy (SBRT/SABR), Cyberknife, Gamma Knife, and high-dose rate (HDR) brachytherapy.
Education & Training
University of Pennsylvania Health SystemResidency, Radiation Oncology, 2016 - 2020- University of Pennsylvania Health SystemInternship, Internal Medicine, 2015 - 2016
University of California San Diego School of MedicineClass of 2014, MD/MAS
Certifications & Licensure
CA State Medical License 2022 - 2026
FL State Medical License 2020 - 2024
PA State Medical License 2015 - 2021- American Board of Radiology Radiation Oncology
- American Heart AssociationACLS
- National CPR FoundationBLS
Publications & Presentations
PubMed
- 1 citationsSMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma.Emily J Anstadt, Ruben Carmona, Eva Berlin, Nikhil Yegya-Raman, Sriram Venigalla
Cancer. 2024-02-01 - 2 citationsED visits, hospital admissions and treatment breaks in head/neck cancer patients undergoing radiotherapy.Shareen Patel, Benjamin J Rich, Leif-Erik D Schumacher, Zoukaa B Sargi, Melissa Masforroll
Frontiers in Oncology. 2023-01-01 - 2 citationsAssessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patie...Neal Andruska, Temitope Agabalogun, Benjamin W Fischer-Valuck, Randall J Brenneman, Yi Huang
Brachytherapy. 2022-05-28
Press Mentions
Omega Factor: Novel Method Measures Mortality Risk When Multiple Diseases ThreatenApril 11th, 2016
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
